Key facts
- Notable investors include Lapam Capital, Hangzhou Yuhang State-owned Capital Investment and Operation Group, Million Capital, Sunz Fund, Xinghua Dingli Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Phecda Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Phecda Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phecda Medicine
Developer of new drugs intended for hospitals, research institutions, and healthcare providers. The company focuses on mitochondrial autophagy inducers and tumor immune enhancers, providing patients with new treatment options for kidney diseases, autoimmune diseases, and aging-related diseases.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 36
- Website
- phecda-med.com/
- Ownership
- Privately Held (backing)
Phecda Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phecda Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phecda Medicine in its N-PORT filings yet. We sweep new filings monthly.